Sysmex Middle East
Menu

Monocytosis Workflow Optimisation

Where do you set your MONO# cut-off for smears? Balancing the burden of the smear workload with the risk of missing critical samples is not easy. The Monocytosis Workflow Optimisation (MWO) offers an evidence-based* optional rule set embedded in the Extended IPU to distinguish reactive monocytosis from monocytosis of suspected malignant origin.

Features

Monocytosis management – The dilemma with selecting the optimum criteria for morphological review

Existing criteria for monocytosis management differ in the MONO cut-off criteria - ISLH/GFHC suggest a smear review for MONO# > 1.5 x103/µL, while according to the WHO (2022), chronic myelomonocytic leukaemia (CMML), a rare leukaemia, is characterised by a MONO# ≥ 0.5 x 103/μL and ≥ 10% of the WBC count.

Reactive cases are most commonly the cause of monocytosis. However, there is a small possibility that the monocytosis is of malignant origin. This suspicion leads to microscopic examination, generating a high number of unnecessary smears. This leads to the dilemma of finding a balance between a significant increase of smears on false-positive samples to not miss a single case of suspected CMML and the reduction of the manual workload with the inherent risk of missing a rare abnormality due to a low sensitivity for CMML detection. 

The MWO concept - How does it work?

MWO combines the so-called ‘mono-dysplasia score’, the monocyte counts and information from the WDF scattergram to recommend samples with monocytosis for microscopic examination. 

The ‘mono-dysplasia score’, established and assessed by Schillinger et al., is calculated from three analytical components obtained from the WDF measurement in the search for dysplastic abnormalities typical for CMML.

Parameters

  • Mono #
  • Neut #/Mono #
  • NE-WX

Scatterplot showing the dispersion of the neutrophil population from which the NE-WX is obtained

 

References

*Schillinger F et al. (2018): A new approach for diagnosing chronic myelomonocytic leukemia using structural parameters of Sysmex XNTM analyzers in routine laboratory practice. Scand J Clin Lab Invest. Vol. 78(3):159–164.

Contacts
You have a question and would like to get in touch with our experts? We look forward to receiving your enquiry.

Sysmex Middle East FZ-LLC

Dubai Healthcare City

City Pharmacy Building C/P 72, Office 304

P.O. Box 505119 Dubai, U.A.E.

+971 4 4370515

+971 4 4370516

Documents

Product documents

Regulatory Documents

Regulatory documents, such as Instructions for Use, can be accessed with a valid My Sysmex login:

Go to My Sysmex

Explore more

XR-1000

XR-1000

Sysmex’s fully automated flagship haematology analyser

Details
SP-50

SP-50

Fully automated slide preparation and staining system

Details
DI-60

DI-60

Fast and accurate, safe and connected!

Details
Extended IPU
Extended IPU
Copyright © Sysmex Europe SE. All rights reserved.